Technology

oligoDOM®: A Novel Proprietary Virus-Like-Particles Technology specifically designed to trigger superior T-cell responses, in addition to strong and sustained B-cell responses

The core concept

Virus-Like-Particles (VLP) self-assemble to present key immunogenic structures of a specific virus in repetition to induce an innate immune response.

Improving and surpassing the VLP technology

oligoDOM® has been uniquely designed to increase the T-cell immune response to the native antigen thanks to a specific signal sequence targeting and activating cells from the immune system.

Building upon the established VLP concept

Like other self-assembling VLP technologies, oligoDOM® also triggers a strong B-cell response by transforming a small, non-immunogenic, native antigen into a large nanoparticle which is easily detected by the immune system, exposing multiple copies of the native antigen.

When associated to an antigen, oligoDOM® forms a unique self-assembling VLP, exposing multiple copies of full-length antigens

Given its design and mechanism of action, the oligoDOM® technology platform is highly versatile and can be used with different antigens, as well as within different vaccine technologies such as recombinant proteins, or mRNA technology, leading to multiple value generation opportunities.

 

Osivax’s lead candidate is a universal influenza vaccine. OVX836 recombinant protein vaccine is currently in phase 2a clinical trials. Osivax is rapidly expanding its portfolio in other areas (such as HPV or Covid-19 with OVX033).

Preventing the Spread of constantly mutating Global Infectious Diseases

Viruses such as influenza constantly mutate making it difficult to accurately predict each year’s virus variants. Most conventional vaccines target highly mutating surface structures, a method that provides suboptimal protection, especially in vulnerable populations such as the elderly.

Osivax is pioneering a universal vaccine which will uniquely empower both the B-cell and the T-cell immune responses. Osivax will combine its best-in-class T-cell component with conventional flu vaccines to fully empower both arms of the immune system.

Thanks to its oligoDOM® technology, Osivax’ vaccines can trigger a T-cell immune response that targets internal and invariant parts of a virus to provide universal protection against both current and future virus strains or variants.

The innovative oligoDOM® technology, an improved self-assembling VLP approach, targets internal and invariant parts of viruses in a very powerful way

References

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine. 
Leroux-Roels I, Waerlop G, Tourneur J, De Boever F, Maes C, Bruhwyler J, Guyon-Gellin D, Moris P, Del Campo J, Willems P, Leroux-Roels G, Le Vert A, Nicolas F.
April 2022. doi: 10.3389/fimmu.2022.852904

Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results. 
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P.
Oct. 2021. doi: 10.1093/infdis/jiab532

OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza. 
Del Campo J, Bouley J, Chevandier M, Rousset C, Haller M, Indalecio A, Guyon-Gellin D, Le Vert A, Hill F, Djebali S, Leverrier Y, Marvel J, Combadière B and Nicolas F. 
June 2021. doi: 10.3389/fimmu.2021.678483

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes. 
Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin M-E, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F. 
Jan. 2019. doi: 10.1038/s41541-019-0098-4.

Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine. 
Zhao X, Yang F,  Mariz F,  Osen W,  Bolchi A,  Ottonello S,  Müller M.
2020 Sep.  e1008827. doi: 10.1371/journal.ppat.1008827

Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses.
Pouyanfard S, Spagnoli G, Bulli L, Balz K, Yang F, Odenwald C, Seitz H, Mariz FC, Bolchi A, Ottonello S, Müller M.
2018 Feb. J Virol 92:e01930-17. doi: 10.1128/JVI.01930-17.

Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.
Spagnoli G, Pouyanfard S, Cavazzini D, Canali E, Maggi S, Tommasino M, Bolchi A, Müller M, Ottonello S.
Sci Rep. 2017; 7: 18000. Published online 2017 Dec 21. doi: 10.1038/s41598-017-18177-1.

SnoopLigase peptide-peptide conjugation enables modular vaccine assembly 
Andersson AC, Buldun CM, Pattinson DJ, Draper SJ, Howarth M.Sci Rep.
2019 Mar 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice. 
Brod F, Miura K, Taylor I, Li Y, Marini A, Salman AM, Spencer AJ, Long CA, Biswas S.Front Immunol.
2018 Dec 4;9:2780. doi: 10.3389/fimmu.2018.02780.

​Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization. 
Brune KD, Buldun CM, Li Y, Taylor IJ, Brod F, Biswas S, Howarth M.Bioconjug Chem.
2017 May 17;28(5):1544-1551. doi: 10.1021/acs.bioconjchem.7b00174.

HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.
Tomusange K, Wijesundara D, Gummow J, Garrod T, Li Y, Gray L, Churchill M, Grubor-Bauk B, Gowans EJ.Sci Rep.
2016 Jun 30;6:29131. doi: 10.1038/srep29131.

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y, Leneghan DB, Miura K, Brian IJ, Dicks MD, Fyfe AJ, Zakutansky SE, De Cassan S, Long CA, Draper SJ, Hill AV, Hill F, Biswas S. Sci Rep.
2016 January 8;6:18848. doi: 10.1038/srep18848.

T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein.
Forbes EK, de Cassan SC, Llewellyn D, Biswas S, Goodman AL, Cottingham MG, Long CA, Pleass RJ, Hill AV, Hill F, Simon J. Draper. PLoS ONE.
2012 September;7(9):e44943. doi:10.1371/journal.pone.0044943.

Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.
Spencer AJ, Hill F, Honeycutt JD, Cottingham MG, Bregu M, Rollier CS, Furze J, Draper SJ, Søgaard KC, Gilbert SC, Wyllie DH, Hill AVS. PLoS ONE.
2012 March;7(3): e33555. doi:10.1371/journal.pone.0033555.

Immunocontraception in male feral swine treated with a recombinant gonadotropin-releasing hormone vaccine.
Campbell TA, Garcia MR, Miller LA, Ramirez MA, Long DB, Marchand JB, Hill F. JSHAP.
May 2010; 18(3):118-124​.

The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria.
Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F. Infect Immun.
2008 Aug;76(8):3817-3823. doi:10.1128/IAI.01369-07.

Effective induction of high-titer antibodies by viral vector vaccines.
Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV. Nat Med.
2008 Aug;14(8):819-821. doi: 10.1038/nm.1850.